Physician profile
Mo Mai
NPI 1306333646
$5,017.58
in general payments reported to CMS, 2019-2025
29 companies · $2,870 in 2025
The $2,870 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.81 · 2024: $2,132 · 2025: $2,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,636 · Travel and Lodging: $342 · Education: $38.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.34 |
| Travel and Lodging | $342.39 |
| Education | $38.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $701.41 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $557.68 | 2024-2025 | Minimed 780g |
| Corcept Therapeutics | $531.68 | 2024-2025 | Korlym |
| Renalytix Ai, INC. | $388.14 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $381.06 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.10 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $312.53 | 2024-2025 | |
| Lilly USA, LLC | $307.07 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $185.02 | 2024-2025 | Tepezza, Repatha, Evenity |
| Abbvie INC. | $184.25 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $128.81 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $121.60 | 2024-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $111.19 | 2024-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $95.95 | 2024-2025 | |
| Ibsa Pharma INC. | $92.83 | 2024-2025 | Licart, Tirosint, Flector |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avvisto Therapeutics, LLC | $91.08 | 2024-2025 | Cycloset |
| Nevro Corp. | $73.28 | 2024 | Senza |
| Kyowa Kirin, INC. | $67.49 | 2024-2025 | Crysvita |
| Sequel Med Tech, LLC | $67.06 | 2025 | Twiist |
| Dexcom, INC. | $62.64 | 2024-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $45.23 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $36.74 | 2024 | Strensiq |
| Tandem Diabetes Care, INC. | $28.47 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $25.00 | 2024 | Farxiga |
| Mannkind Corporation | $21.31 | 2024 | |
| Astellas Pharma US INC | $19.42 | 2024 | Veozah |
| Averitas Pharma INC. | $18.55 | 2025 | Qutenza |
| Amneal Pharmaceuticals LLC | $16.72 | 2025 | Unithroid |
| Beta Bionics, INC. | $9.27 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mo Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.